Bristol-Myers Squibb Co (NYSE:BMY) was the target of a significant drop in short interest during the month of March. As of March 29th, there was short interest totalling 48,063,938 shares, a drop of 26.9% from the March 15th total of 65,779,147 shares. Based on an average daily volume of 18,357,735 shares, the days-to-cover ratio is currently 2.6 days. Approximately 2.9% of the company’s shares are short sold.

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc. now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after purchasing an additional 1,229,553 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after purchasing an additional 1,229,553 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Bristol-Myers Squibb by 0.9% during the fourth quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after purchasing an additional 999,193 shares in the last quarter. Dodge & Cox lifted its stake in shares of Bristol-Myers Squibb by 0.8% during the third quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock worth $2,046,727,000 after purchasing an additional 264,100 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Bristol-Myers Squibb by 4.4% during the fourth quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock worth $1,173,547,000 after purchasing an additional 954,877 shares in the last quarter. Institutional investors own 74.27% of the company’s stock.

BMY has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Tuesday, March 5th. BMO Capital Markets reiterated a “buy” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a report on Thursday, January 3rd. Credit Suisse Group reiterated a “hold” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a report on Friday, February 15th. Bank of America reduced their target price on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a report on Tuesday, February 19th. Finally, Morgan Stanley set a $54.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, December 20th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $59.13.

Shares of Bristol-Myers Squibb stock opened at $45.57 on Monday. Bristol-Myers Squibb has a twelve month low of $44.30 and a twelve month high of $63.69. The firm has a market capitalization of $75.25 billion, a P/E ratio of 11.45, a PEG ratio of 2.37 and a beta of 0.79. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The firm had revenue of $5.97 billion for the quarter, compared to analysts’ expectations of $5.95 billion. During the same quarter last year, the firm earned $0.68 earnings per share. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. As a group, equities research analysts predict that Bristol-Myers Squibb will post 4.16 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

ILLEGAL ACTIVITY WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-co-bmy-short-interest-update-2/2962898.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: What is Put Option Volume?

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.